IV Antibiotics for Non-Purulent Cellulitis in Adults
For an adult with non-purulent cellulitis and no drug allergies requiring IV therapy, cefazolin is the recommended first-line agent, with modification to vancomycin, linezolid, daptomycin, or telavancin if there is no clinical response within 48-72 hours.
Primary Recommendation: Beta-Lactam First
The IDSA guidelines consistently emphasize that non-purulent cellulitis (cellulitis without purulent drainage, exudate, or abscess) is primarily caused by beta-hemolytic streptococci, not MRSA 1, 2, 1, 2. Therefore:
- Start with IV cefazolin (1 g every 8 hours) as the beta-lactam of choice for hospitalized patients 2
- This provides excellent streptococcal coverage with a convenient dosing schedule and less bone marrow suppression than nafcillin 3
- Alternative beta-lactams include nafcillin or oxacillin (1-2 g every 4 hours IV) 3
When to Add or Switch to MRSA Coverage
The guidelines are clear about the algorithmic approach:
Switch to MRSA-active therapy if:
- No clinical response to beta-lactam within 48-72 hours 1, 2, 1
- Patient has systemic toxicity at presentation 1, 2, 1, 2
MRSA-active IV options (in order of evidence strength):
- Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (A-I evidence) 1, 2, 1
- Linezolid 600 mg IV twice daily (A-I evidence) 1, 2, 1
- Daptomycin 4 mg/kg/dose IV once daily (A-I evidence) 1, 2, 1
- Telavancin 10 mg/kg/dose IV once daily (A-I evidence) 1, 2, 1
- Clindamycin 600 mg IV three times daily (A-III evidence) 1, 2, 1
Critical Clinical Context
The role of CA-MRSA in non-purulent cellulitis remains unknown 1, 2, 1, 2. This is a crucial distinction from purulent cellulitis, where MRSA coverage is recommended upfront. The evidence consistently shows that empirical MRSA coverage for non-purulent cellulitis is only warranted after beta-lactam failure or in the presence of systemic toxicity.
Duration and Monitoring
- 7-14 days total therapy is recommended, individualized based on clinical response 1, 2, 1
- Transition to oral therapy when the area of cellulitis stops advancing (typically 1-2 days) 4
- Monitor for clinical improvement: decreased erythema, reduced warmth, resolution of fever
Common Pitfalls to Avoid
Do not automatically use vancomycin for all hospitalized cellulitis patients. The guidelines explicitly state that a beta-lactam should be considered first for non-purulent cellulitis 1, 2, 1. Overuse of vancomycin contributes to resistance and exposes patients to unnecessary nephrotoxicity and infusion reactions.
Do not confuse non-purulent cellulitis with purulent cellulitis or abscess. Purulent infections require upfront MRSA coverage, while non-purulent cellulitis does not 1, 2, 1, 2.
Bilateral cellulitis is rare 5. If you see bilateral lower extremity erythema, strongly consider alternative diagnoses such as venous stasis dermatitis or dependent edema rather than infection.